4565.T
Nxera Pharma Co.,Ltd.
プライム · 医薬品 · 医薬品 · JP
JPY 1,180.00
+2.61%Year over year
Reported trailing growth
- Revenue
- +10.9%
- EBITDA
- —
- EBIT
- +33.4%
- EPS
- —
- Free cash flow
- -1.6%
- Operating cash flow
- -0.7%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +23.9%
- EBITDA
- —
- EBIT
- -56.0%
- Net income
- —
- EPS
- —
- Free cash flow
- +62.2%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026